Group items tagged

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The purpose of the LungMAP RCs will be to generate the molecular profiling data of the developing human lung. Applicants are not required to have been funded in Phase 1 (RFA-HL-14-008) in order to submit applications for Phase 2.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR ) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful , proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

This NASA Research Announcement (NRA) solicits proposals for supporting basic and applied research and technology across a broad range of Earth and space science program elements relevant to one or more of the following NASA Research Programs: Earth Science, Heliophysics, Planetary Science, and Astrophysics. This ROSES NRA covers all aspects of basic and applied supporting research and technology in space and Earth sciences, including, but not limited to: theory, modeling, and analysis of SMD science data; aircraft, stratospheric balloon, suborbital rocket, and commercial reusable rocket investigations; development of experiment techniques suitable for future SMD space missions; development of concepts for future SMD space missions; development of advanced technologies relevant to SMD missions; development of techniques for and the laboratory analysis of both extraterrestrial samples returned by spacecraft, as well as terrestrial samples that support or otherwise help verify observations from SMD Earth system science missions; determination of atomic and composition parameters needed to analyze space data, as well as returned samples from the Earth or space; Earth surface observations and field campaigns that support SMD science missions; development of integrated Earth system mo dels; development of systems for applying Earth science research data to societal needs; and development of applied information systems applicable to SMD objectives and data.

nationally designated and highly visible corporate, non-profit, and federal research and development centers or laboratory facilities (hereafter referred to as Center(s)) to Ohio. The Industrial Research and Development Center Program will achieve this goal by enhancing and supplementing Ohio organizations' proposals for such Centers by providing funding that serves as cost share or matching dollars, thereby improving the competitiveness of the proposal and enhancing the potential for a Center being located in Ohio.   The specific goals and objectives of the Industrial Research and Development Center Program are to: ·         Secure new-to-Ohio research and development funding and facilities with "center" designations by their primary sponsor; ·         Increase the reputation and visibility of Ohio within selected fields of research and development that are aligned with Ohio Third Frontier technology focus areas; ·         Provide support for Centers that will conduct applied research, commercialize new technologies and innovations, support Ohio companies and their efforts to launch new, innovative products, and address competitiveness issues of industries that are strategically significant to Ohio. ·         Attract exceptional senior talent from industry and outside Ohio with demonstrated entrepreneurial qualities and attributes that integrates and aligns well to Center-driven, and their own, commercial outcomes and extended talent development; and, ·         Create new, high-tech jobs.

The Therapeutic Idea Award is designed to promote new ideas aimed at drug, treatment, and target discovery that are still in the early stages of development. Proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this mechanism.New for FY15: In addition to hypothesis-based ideas aimed at drug or treatment discovery, the FY15 Therapeutic Idea Award will support the following topics, which were previously supported under the ALSRP Therapeutic Development Award mechanism. Development, validation, and application of high-throughput screens to define targets with therapeutic potential or to identify lead agent candidates for ALS treatment; Development, modification, and/or validation of preclinical model systems in order to assess lead compounds and potential therapeutics by pharmacological and/or pharmacokinetic testing. Such models would also serve as improved tools for the ALS research community.Applicants contemplating development of products beyond drug or treatment discovery should apply to the ALSRP Therapeutic Development Award, which supports advanced preclinical development activities.Innovation and impact are the most important aspects of the Therapeutic Idea Award. Applications that demonstrate exceptional scientific merit but lack innovation and highDoD FY15 ALSRP Therapeutic Idea Award 4potential impact do not meet the intent of the Therapeutic Idea Award. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative idea and the potential impact it will provide.

This ROSES-2014 NRA (NNH14ZDA001N) solicits basic and applied research in support of NASA's Science Mission Directorate (SMD). This NRA covers all aspects of basic and applied supporting research and technology in space and Earth sciences, including, but not limited to: theory, modeling, and analysis of SMD science data; aircraft, scientific balloon, sounding rocket, International Space Station, CubeSat, and suborbital reusable launch vehicle investigations; development of experiment techniques suitable for future SMD space missions; development of concepts for future SMD space missions; development of advanced technologies relevant to SMD missions; development of techniques for and the laboratory analysis of both extraterrestrial samples returned by spacecraft, as well as terrestrial samples that support or otherwise help verify observations from SMD Earth system science missions; determination of atomic and composition parameters needed to analyze space data, as well as returned samples from the Earth or space; Earth surface observations and field campaigns that support SMD science missions; development of integrated Earth system models; development of systems for applying Earth science research data to societal needs; and development of applied information systems applicable to SMD objectives and data. 

This ROSES-2014 NRA (NNH14ZDA001N) solicits basic and applied research in support of NASA's Science Mission Directorate (SMD). This NRA covers all aspects of basic and applied supporting research and technology in space and Earth sciences, including, but not limited to: theory, modeling, and analysis of SMD science data; aircraft, scientific balloon, sounding rocket, International Space Station, CubeSat, and suborbital reusable launch vehicle investigations; development of experiment techniques suitable for future SMD space missions; development of concepts for future SMD space missions; development of advanced technologies relevant to SMD missions; development of techniques for and the laboratory analysis of both extraterrestrial samples returned by spacecraft, as well as terrestrial samples that support or otherwise help verify observations from SMD Earth system science missions; determination of atomic and composition parameters needed to analyze space data, as well as returned samples from the Earth or space; Earth surface observations and field campaigns that support SMD science missions; development of integrated Earth system models; development of systems for applying Earth science research data to societal needs; and development of applied information systems applicable to SMD objectives and data.

In May of 2013 the National Institute of Neurological Disorders and Stroke (NINDS), with input from the National Institute on Aging (NIA), held an Alzheimer's Disease-Related Dementias Conference in response to the National Plan to Address Alzheimer's Disease. The Conference brought together national and international experts and members of the public to develop research priorities for accelerating the development of therapies for the Alzheimer's disease-related dementias (ADRDs). The ADRD 2013 research recommendations that resulted are part of the National Plan to Address Alzheimer's Disease. This FOA addresses the National Plan's highest priority for human-based research on vascular contributions to cognitive impairment and dementia (VCID): to develop noninvasive markers of key vascular processes related to VCID in Alzheimer's and related dementias. The research program initiated here underscores the need to facilitate the development of biomarkers to improve the efficiency and outcome of Phase II and III clinical trials and advance therapeutic development. These companion FOAs (RFA-NS-16-019, i.e. this FOA; and RFA-NS-16-020 for the Biomarkers Development Projects) establish the Small Vessel VCID Biomarkers Consortium, and are focused on small vessel (i.e. arterioles, capillaries, and venules) VCID in vascular cognitive impairment (VCI), vascular dementia, and all mixed and pure cognitive impairment and dementias with contributing small vessel vascular disease, including such as commonly occurs in sporadic Alzheimer's disease. Awards funded under these two FOAs create a consortium and infrastructure to complete development projects as well as planning that will enable follow-up activities (to be carried out under future separate funding; for example large scale multi-site validation studies and other activities, for future FDA qualification of small vessel VCID biomarkers and use in clinical trials).

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field.

The overall objective of the LungMAP is to better understand human lung development by building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 1 of the LungMAP has generated foundational data from developing mouse and human lungs, created a web portal for public data sharing, and established a repository of human lung tissues. Phase 2 of the LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult companion FOAs listed above.

The purpose of this announcement is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women.  This FOA expands the scope of the former program by calling for Centers to inform contraceptive development and improve contraceptive use by integrating the biomedical research and development with behavioral and social science research, e.g., demography and other population sciences, psychology, economics, and sociology.  These Centers also will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

The purpose of this announcement is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women.  This FOA expands the scope of the former program by calling for Centers to inform contraceptive development and improve contraceptive use by integrating the biomedical research and development with behavioral and social science research, e.g., demography and other population sciences, psychology, economics, and sociology.  These Centers also will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

The Greenwall Foundation is soliciting Letters of Intent for its Greenwall Faculty Scholars Program in Bioethics, a career development award designed to enable junior faculty members to carry out innovative bioethics research. Each year, around three Greenwall Faculty Scholars are selected to receive 50 percent salary support for three years to enable them to develop their research program. The program supports research focused on resolving pressing ethical issues in clinical care, biomedical research, and public policy. Scholars and alumni attend twice-yearly meetings, where they present their work in progress, receive feedback and mentoring from the Faculty Scholars Program Committee and other scholars, and have the opportunity to develop collaborations with other researchers. The ongoing involvement of alumni with the program provides them ongoing opportunities for professional development and feedback and engages them in mentoring of younger scholars.

The Greenwall Foundation is soliciting Letters of Intent for its Greenwall Faculty Scholars Program in Bioethics, a career development award designed to enable junior faculty members to carry out innovative bioethics research. Each year, around three Greenwall Faculty Scholars are selected to receive 50 percent salary support for three years to enable them to develop their research program. The program supports research focused on resolving pressing ethical issues in clinical care, biomedical research, and public policy. Scholars and alumni attend twice-yearly meetings, where they present their work in progress, receive feedback and mentoring from the Faculty Scholars Program Committee and other scholars, and have the opportunity to develop collaborations with other researchers. The ongoing involvement of alumni with the program provides them ongoing opportunities for professional development and feedback and engages them in mentoring of younger scholars.

During the last nine years, the U.S. Centers of Disease Control and Prevention (CDC) has worked with nations around the world to build capacity to prepare, detect, and respond to pandemics. Through previous funding opportunity announcements (FOA) and subsequent cooperative agreements, CDC and its international partners and national ministries of health focused on three pillars: 1) preparedness and communication; 2) surveillance and detection; 3) response and containment. The success of this developed capacity is evident across the globe. Through these cooperative agreements, CDC and partners have: Developed national government public-health pandemic preparedness plans Developed pandemic communication plans Improved laboratory capacity and infrastructure for influenza virologic surveillance Enhanced epidemiology capacity and infrastructure for disease surveillance Developed sentinel, hospital-based surveillance for severe acute respiratory illness (SARI) Enhanced integration of laboratory and epidemiologic surveillance for influenza Developed surveillance for cases and clusters of respiratory and febrile illnesses that could represent emerging new pandemics. Trained local rapid-response and containment teams. Developed infection control guidelines in public health-care settings for the prevention of avian and pandemic flu. It is critical that these new capacities be sustained and strengthened over time to ensure global capacity to detect and respond to pandemic influenza effectively.

This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).

This Broad Agency Announcement (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address Zimbabwe's Development Challenges. Those Development Challenges may include opportunities to increase the number of Zimbabweans who live longer, healthier lives. The United States Agency for International Development (USAID) invites individuals, organizations, and companies to participate with the USAID Mission in Zimbabwe (USAID/Zimbabwe) to create more strategic, focused and results- oriented solutions to respond to the development challenges in Zimbabwe.

The NIH is interested in promoting a broad base of research and development of technologies in biomedical computing, informatics, and Big Data Science that will support rapid progress in areas of scientific opportunity in biomedical research. It is expected that this research and development is conducted in the context of important biomedical and behavioral research problems. As such, applications are intended to develop enabling technologies that could apply to the interests of most NIH Institutes and Centers and range from basic biomedicine and including research to all relevant organ systems and diseases. Major themes of research include collaborative environments; data integration; analysis and modeling methodologies; and novel computer science and statistical approaches. New opportunities are also emerging as large and complex data sets are becoming increasingly available to the research community. This initiative aims to address biomedical research areas in biomedical computing, informatics, and Big Data science through the early stage development of new software, tools and related resources, as well as the fundamental research (e.g., methodologies and approaches) leading up to that development.

The purpose of the Field Initiated (FI) Projects program is to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities. Another purpose of the FI Projects program is to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended. The purpose of this MSI-FI competition is to improve the capacity of minority entities to engage in disability and rehabilitation research and development activities. NIDILRR will accomplish this by limiting eligibility for this completion to minority entities and Indian tribes in a manner consistent with Sections 21(b)(2)(A) of the Act, which authorizes NIDILRR to make awards to minority entities and Indian tribes to carry out activities authorized under Title II of the Act. NIDILRR is particularly interested in applications from individual minority entities that have historically been underrepresented in the Federally-sponsored research arena. In carrying out a development activity under a FI Projects development grant, a grantee must use knowledge and understanding gained from research to create materials, devices, systems, methods, measures, techniques, tools, protypes, processes, or intervention protocols that are beneficial to the target population. Please note that this will be the funding opportunity for FI development proposals for minority-serving institutions.